Evidence map›Paper›PMID 39590162›Full record

SynthesisCurrent oncology (Toronto, Ont.)2024

Immunotherapy Responses in Viral Hepatitis-Induced HCC: A Systematic Review and Meta-Analysis.

Junaid Anwar, Hafiz Muhammad Arslan, Zouina Sarfraz, Juwairiya Shuroog, Ahmed Abdelhakeem, Ali Saeed, Anwaar Saeed

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. [Research progress on poor response, resistance mechanisms, and influencing factors of immunotherapy for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junaid AnwarDepartment of Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA.
Hafiz Muhammad ArslanDepartment of Medicine, Lincoln Medical and Mental Health Center, Bronx, NY 10451, USA.
Zouina SarfrazDepartment of Medicine, Fatima Jinnah Medical University, Lahore 54000, Pakistan.ORCID 0000-0002-5132-7455
Juwairiya ShuroogDepartment of Medicine, TidalHealth Peninsula Regional, Salisbury, MD 21801, USA.
Ahmed AbdelhakeemDepartment of Medicine, Division of Hematology & Oncology, Mayo Clinic College of Medicine and Science, Jacksonville, FL 32224, USA.ORCID 0000-0001-7186-1332
Ali SaeedDepartment of Medicine, Ochsner Lafayette General Medical Center, Lafayette, LA 70503, USA.
Anwaar SaeedDepartment of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsHepatitis BHepatitis CHepatitis, Viral, HumanHumanscancer treatmentclinical trialshepatitis Bhepatitis Chepatocellular carcinomaimmunotherapyobjective responsepersonalized medicinesurvival

Identifiers

PMID39590162
PMCPMC11592516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.